UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
05 Giugno 2024 - 2:00PM
Business Wire
- Presentation June 11, 2024 at 3:20 PM ET
-
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that management
will participate in a fireside chat at the 45th Annual Goldman
Sachs Global Healthcare Conference to take place June 10-13,
2024.
Goldman Sachs 45th Annual Healthcare
Conference
Date/ time:
June 11, 2024 at 3:20 PM ET
Format:
Fireside Chat
Location:
Miami, FL
Webcast Link:
here
A webcast from the conference will also be available via the
Investors section of UroGen’s corporate website,
https://investors.urogen.com. A replay will be available for
approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel reverse-thermal hydrogel, a proprietary
sustained-release, hydrogel-based platform technology that has the
potential to improve the therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Our first
product to treat LG-UTUC and investigational treatment UGN-102
(mitomycin) for intravesical solution for patients with low-grade
non-muscle invasive bladder cancer are designed to ablate tumors by
non-surgical means. UroGen is headquartered in Princeton, NJ with
operations in Israel. To learn more, visit www.UroGen.com or follow
us on X (Twitter), @UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240605807048/en/
INVESTOR CONTACT:
Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
Grafico Azioni UroGen Pharma (NASDAQ:URGN)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni UroGen Pharma (NASDAQ:URGN)
Storico
Da Set 2023 a Set 2024